Ticlopidine
TICIOPIDINE · pcr5332 · PCR 5332 · Ticlosin · Anagregal · Caudaline · TICLOPIDINE · PCR 5332|||Ticlid
식별자 및 물리적 특성
| CAS No. | 55142-85-3 |
|---|---|
| 분자식 | C14H14ClNS |
| 평균 분자량 | 263.8 g/mol |
| 단동위원소 질량 | 263.05354813 g/mol |
| SMILES | Clc1ccccc1CN1CCc2sccc2C1 |
| InChIKey | PHWBOXQYWZNQIN-UHFFFAOYSA-N |
| PubChem CID | 5472 |
| ChEMBL | CHEMBL833 |
| ChEBI | CHEBI:9588 |
| EC No. | 259-498-5 |
| DTXSID | DTXSID5023669 |
화학 및 물리적 성질
| XLogP | 3.6 |
|---|---|
| 극성 표면적 | 31.5 |
| 수소 결합 공여자 수 | 0 |
| 수소 결합 수용자 수 | 2 |
| 회전 가능 결합 수 | 2 |
| 무거운 원자 수 | 17 |
| 형식 전하 | 0 |
| 복잡도 | 261 |
| 의약품 | Pharmaceuticals -> Listed in ZINC15 |
| LogP(분배 계수) | 2.93.46 |
| 용해도 | Freely soluble2.19e-02 g/L1 [ug/mL] (The mean of the results at pH 7.4)클로로포름(약간 용해됨), DMSO(약간 용해됨), 메탄올(약간 용해됨) |
| 녹는점 | approx. 1 189°C210-212 °C |
| Physical Description | Solid |
| Collision Cross Section | 156.8 Ų [M+H]+ [CCS Type: DTBuffer gas: N2Ionization: ESI+Dataset: TOXCASTSource Identifier: DTXSID80202141]153.84 Ų [M+H]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards] |
| 끓는 점 | 117-120 °C(Press: 0.5 Torr) |
| 밀도 | 1.273±0.06 g/cm3(Predicted) |
| 저장 조건 | 2-8°C(protect from light) |
| 물리적 상태 | 고체 |
| pKa(산도 계수) | 7.10±0.20(Predicted) |
| 색상 | 황백색에서 연한 노란색 |
| NIST | Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-(55142-85-3) |
| EPA | Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro- (55142-85-3) |
안전 및 규제
| 기타 안전 정보 | IMAP assessments - Thieno[3,2-c]pyridine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydro-: Environment tier I assessment |
|---|---|
| Hepatotoxicity | Ticlopidine has been associated with serum enzyme elevations in approximately 4% of patients during therapy. These elevations are usually mild, asymptomatic and rarely require dose modification or stopping. Ticlopidine has also been associated with clinically apparent, acute liver injury. While these reactions are rare, more than 50 instances have been reported in the literature and some have been severe. The onset of symptoms is typically within 6 weeks (range 1 to 24 weeks) and marked by onset with fatigue, jaundice and itching. The usual pattern of liver enzyme elevations is cholestatic (~75%), but cases with mixed or hepatocellular enzyme elevations have also been described. Immunoallergic features such as fever, rash and eosinophilia can occur but are not common and, if present, are usually mild. Autoantibody formation is rare. Liver biopsy usually shows cholestatic hepatitis with mixed cellular infiltrates. Most cases are self-limited with recovery within 1 to 3 months, but isolated cases of prolonged jaundice or liver test abnormalities have been described, including at least one case of probable vanishing bile duct syndrome that eventually required liver transplantation. Ticlopidine therapy has also been associated with aplastic anemia and thrombotic thrombocytopenic purpura (TTP) that can be severe and lead to deaththese patients may also have accompanying cholestatic liver injury. |
| Drug Induced Liver Injury | Benchmark Dataset for the Liver Toxicity Knowledge Base (LTKB)ticlopidineTiclidAntithrombotics4most-DILI-concern |
| 기존화학 물질 | KE-05853 |
용도
용도
Ticlopidine suppresses aggregation of thrombocytes and possesses antiaggregant activity. It is believed that its action is connected to its effect on thrombocyte membranes and the reduction in quantity of released adenosine diphosphate and serotonin, which facilitate aggregation of thrombocytes. In wide-ranging clinical trials, ticlopidine presented a number of advantages compared to aspirin.
일반 설명
Ticlopidine, 5-[(2-chlorophenyl)methyl]-4,5,6,7-tetrahydrothieno [3,2-c]pyridine hydrochloride(Ticlid), is useful in reducing cardiac events in patients withunstable angina and cerebrovascular events in secondaryprevention of stroke. It belongs to the thienopyridine classand facilitated the development of clopidogrel. One of thedrawbacks to this agent is its side effect profile, whichincludes neutropenia, and patients receiving this antithromboticshould have their blood levels monitored. Its mechanismof action is similar to that of clopidogrel, in that itinhibits the purinergic receptors on platelets.